高级别胶质瘤（HGG）是成人和儿童群体中最常见且最具侵袭性的原发性脑肿瘤。尽管目前有多种多样的治疗方法用于HGG，但预后令人沮丧，两年生存率低。在过去十年中，溶瘤病毒疗法由于其溶瘤和免疫刺激特性而成为管理这些肿瘤的有希望和可行的治疗工具。已经评估了各种溶瘤病毒，如单纯疱疹病毒、腺病毒、脊髓灰质炎病毒、雷奥病毒、小病毒等，以改善HGG患者的预后，在临床阶段已经取得了积极进展。在这篇综述中，我们总结成人和儿童恶性胶质瘤溶瘤病毒疗法的已完成和正在进行的临床试验，从安全性和疗效方面加以讨论，随后简要探讨了该疗法在脑肿瘤领域的当前地位和未来发展方向。版权所有©2023 Elsevier Inc.保留所有权利。

High-grade gliomas (HGGs) are the most common and aggressive primary brain tumors in both adult and pediatric populations. Despite the multimodal treatment modality currently available for HGG, the prognosis is dismal, with a low overall survival rate at two years after diagnosis. In the last decade, oncolytic virotherapy has emerged as a promising and feasible therapeutic tool in management of these tumors due to its oncolytic and immunostimulatory properties. Various oncolytic viruses, such as herpes simplex virus, adenovirus, poliovirus, reovirus, parvovirus and others, have been evaluated in the early stages of the clinical setting with regard to improving the outcome of patients with HGG. In this review, we summarize completed and ongoing clinical trials of oncolytic virotherapy for adult and pediatric malignant gliomas in terms of safety and efficacy, followed by a brief discussion about the current status and future directions of this therapy in the brain tumor field.Copyright © 2023 Elsevier Inc. All rights reserved.